|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AGBL1 |
Gene summary for AGBL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AGBL1 | Gene ID | 123624 |
| Gene name | AGBL carboxypeptidase 1 | |
| Gene Alias | CCP4 | |
| Cytomap | 15q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A1C7CYX3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 123624 | AGBL1 | RNA-P10T1-P10T1-4 | Human | Lung | AIS | 2.05e-08 | 1.62e+00 | -0.1173 |
| 123624 | AGBL1 | RNA-P10T2-P10T2-1 | Human | Lung | AAH | 1.77e-08 | 1.11e+00 | -0.1271 |
| 123624 | AGBL1 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 5.82e-10 | 1.27e+00 | -0.1406 |
| 123624 | AGBL1 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 1.97e-09 | 1.18e+00 | -0.1408 |
| 123624 | AGBL1 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 3.02e-07 | 1.14e+00 | -0.138 |
| 123624 | AGBL1 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 3.35e-42 | 1.70e+00 | -0.2116 |
| 123624 | AGBL1 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 1.21e-27 | 1.80e+00 | -0.1941 |
| 123624 | AGBL1 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 2.13e-33 | 1.80e+00 | -0.2107 |
| 123624 | AGBL1 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.74e-39 | 1.78e+00 | -0.2119 |
| 123624 | AGBL1 | RNA-P5T2-P5T2-1 | Human | Lung | MIAC | 5.75e-12 | 1.80e+00 | -0.0135 |
| 123624 | AGBL1 | RNA-P5T2-P5T2-3 | Human | Lung | MIAC | 1.25e-04 | 1.25e+00 | 0.0176 |
| 123624 | AGBL1 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 4.21e-10 | 1.01e+00 | -0.0961 |
| 123624 | AGBL1 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 7.47e-16 | 1.27e+00 | -0.0876 |
| 123624 | AGBL1 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 7.13e-10 | 1.04e+00 | -0.0822 |
| 123624 | AGBL1 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 5.94e-15 | 1.15e+00 | -0.0809 |
| 123624 | AGBL1 | RNA-P8T2-P8T2-3 | Human | Lung | AIS | 1.04e-04 | 9.20e-01 | -0.1284 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AGBL1 | SNV | Missense_Mutation | novel | c.1364N>G | p.Thr455Arg | p.T455R | Q96MI9 | protein_coding | tolerated(0.61) | benign(0.001) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| AGBL1 | SNV | Missense_Mutation | novel | c.497N>C | p.Arg166Pro | p.R166P | Q96MI9 | protein_coding | deleterious(0) | possibly_damaging(0.769) | TCGA-A7-A4SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| AGBL1 | SNV | Missense_Mutation | novel | c.2005N>G | p.Phe669Val | p.F669V | Q96MI9 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-A8-A08G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| AGBL1 | SNV | Missense_Mutation | novel | c.2914C>T | p.Leu972Phe | p.L972F | Q96MI9 | protein_coding | tolerated_low_confidence(0.32) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| AGBL1 | SNV | Missense_Mutation | c.189N>T | p.Arg63Ser | p.R63S | Q96MI9 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AR-A1AX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| AGBL1 | SNV | Missense_Mutation | c.835N>A | p.Asp279Asn | p.D279N | Q96MI9 | protein_coding | deleterious(0.03) | benign(0.014) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| AGBL1 | SNV | Missense_Mutation | c.378N>T | p.Leu126Phe | p.L126F | Q96MI9 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-E2-A1IL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| AGBL1 | SNV | Missense_Mutation | rs756401875 | c.2258T>C | p.Ile753Thr | p.I753T | Q96MI9 | protein_coding | deleterious(0) | possibly_damaging(0.864) | TCGA-E9-A1ND-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
| AGBL1 | SNV | Missense_Mutation | rs752268070 | c.370G>A | p.Ala124Thr | p.A124T | Q96MI9 | protein_coding | deleterious(0.03) | probably_damaging(0.994) | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| AGBL1 | deletion | Frame_Shift_Del | novel | c.1289delC | p.Pro430GlnfsTer3 | p.P430Qfs*3 | Q96MI9 | protein_coding | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |